Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
ALDX Quote, Financials, Valuation and Earnings
Last price:
$4.13
Seasonality move
:
4.94%
Day range:
$4.74 - $5.10
52-week range:
$1.14 - $7.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.61x
Volume:
3.4M
Avg. volume:
955.4K
1-year change:
-33.09%
Market cap:
$248.3M
Revenue:
--
EPS (TTM):
-$0.56
Analysts' Opinion
-
Consensus RatingAldeyra Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.67, Aldeyra Therapeutics, Inc. has an estimated upside of 134.34% from its current price of $4.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $4.94.
Fair Value
-
According to the consensus of 4 analysts, Aldeyra Therapeutics, Inc. has 134.34% upside to fair value with a price target of $9.67 per share.
ALDX vs. S&P 500
-
Over the past 5 trading days, Aldeyra Therapeutics, Inc. has underperformed the S&P 500 by -14.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aldeyra Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aldeyra Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Aldeyra Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Aldeyra Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Aldeyra Therapeutics, Inc. reported earnings per share of -$0.11.
Enterprise value:
193.7M
EV / Invested capital:
3.24x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.17x
EV / Free cash flow:
-5.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$252K
Return On Assets:
-39.12%
Net Income Margin (TTM):
--
Return On Equity:
-59.72%
Return On Invested Capital:
-46.89%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$262.8K | -$249.6K | -$252K | -$64.4K | -$65.1K | |
| Operating Income | -$42.8M | -$60.1M | -$35.3M | -$16.6M | -$6.7M | |
| EBITDA | -$42.5M | -$59.9M | -$35M | -$16.5M | -$6.6M | |
| Diluted EPS | -$0.64 | -$0.94 | -$0.56 | -$0.27 | -$0.11 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $232.8M | $178.4M | $143.3M | $101.9M | $70.7M | |
| Total Assets | $233.2M | $181.3M | $148.3M | $104.6M | $72.1M | |
| Current Liabilities | $11.8M | $15.4M | $22.3M | $18.6M | $27.8M | |
| Total Liabilities | $27.5M | $30.3M | $28.5M | $33.6M | $27.8M | |
| Total Equity | $205.7M | $151M | $119.8M | $71M | $44.3M | |
| Total Debt | $15.6M | $15.8M | $15.4M | $15M | $15.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.3M | -$43.2M | -$33.3M | -$12M | -$5.3M | |
| Cash From Investing | $30M | -$44.9M | $47.7M | -$1.6M | $16M | |
| Cash From Financing | -$1.3M | -$171.4K | $1.1M | $7.8K | -- | |
| Free Cash Flow | -$30.3M | -$43.2M | -$33.3M | -$12M | -$5.3M | |
ALDX
Sector
Market Cap
$248.3M
$25.1M
Price % of 52-Week High
58.26%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-0.36%
-1.6%
1-Year Price Total Return
-39.43%
-18.38%
Beta (5-Year)
0.973
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.07
200-day SMA
Buy
Level
$4.82
Bollinger Bands (100)
Sell
Level
4.67 - 5.43
Chaikin Money Flow
Buy
Level
4.9M
20-day SMA
Sell
Level
$5.16
Relative Strength Index (RSI14)
Sell
Level
46.15
ADX Line
Sell
Level
15.69
Williams %R
Buy
Level
-93.3526
50-day SMA
Sell
Level
$5.02
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
229.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.5786)
Sell
CA Score
(Annual)
Level (-1.566)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (3.6711)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Stock Forecast FAQ
In the current month, ALDX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALDX average analyst price target in the past 3 months is $9.67.
-
Where Will Aldeyra Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aldeyra Therapeutics, Inc. share price will rise to $9.67 per share over the next 12 months.
-
What Do Analysts Say About Aldeyra Therapeutics, Inc.?
Analysts are divided on their view about Aldeyra Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aldeyra Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Aldeyra Therapeutics, Inc.'s Price Target?
The price target for Aldeyra Therapeutics, Inc. over the next 1-year time period is forecast to be $9.67 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aldeyra Therapeutics, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALDX?
You can purchase shares of Aldeyra Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aldeyra Therapeutics, Inc. shares.
-
What Is The Aldeyra Therapeutics, Inc. Share Price Today?
Aldeyra Therapeutics, Inc. was last trading at $4.13 per share. This represents the most recent stock quote for Aldeyra Therapeutics, Inc.. Yesterday, Aldeyra Therapeutics, Inc. closed at $4.94 per share.
-
How To Buy Aldeyra Therapeutics, Inc. Stock Online?
In order to purchase Aldeyra Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ALDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALDX
Sector
P/E ratio
--
21.37x
PEG ratio
-0.17x
-0.01x
P/B ratio
5.61x
1.73x
Price / LTM sales
--
1.46x
Growth Metrics
ALDX
Sector
Revenue growth
--
3.27%
Earnings growth
59.53%
12.13%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.15
-$0.20
Profitability
ALDX
Sector
Profitability FY 2025
-$252K
$2.3M
Return on invested capital
-46.89%
-33.43%
Return on assets
-39.12%
-29.94%
Return on equity
-59.72%
-40.07%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
May
15
Estimated Next Earnings Date
Jun
4
Balance Sheet
ALDX
Sector
Total cash
$70M
$24.9M
Short term investments
$46.6M
$23M
Total assets
$72.1M
$70.1M
Long term debt
$15.2M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
